<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02159716</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 31213, 819826</org_study_id>
    <nct_id>NCT02159716</nct_id>
  </id_info>
  <brief_title>CART-meso in Mesothelin Expressing Cancers</brief_title>
  <official_title>Phase I Study of Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I study to establish safety and feasibility of intravenously administered lentiviral&#xD;
      transduced CART-meso cells administered with and without cyclophosphamide in a 3+3 dose&#xD;
      escalation design in patients with metastatic pancreatic cancer, serous epithelial ovarian&#xD;
      cancer, or pleural mesothelioma. Dose: 1-3xE7 /mE2 (Cohort 1 and 2) and 1-3xE8 /mE2 (Cohort 3&#xD;
      and 4 ) CAR+ T cells by intravenous route. In the event of 2 DLTs at each dose level, we will&#xD;
      dose deescalate by 10-fold.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Metastatic Pancreatic (Ductal) Adenocarcinoma</condition>
  <condition>Epithelial Ovarian Cancer</condition>
  <condition>Malignant Epithelial Pleural Mesothelioma</condition>
  <arm_group>
    <arm_group_label>Metastatic Pancreatic (ductal) adenocarcinoma (PDA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Serious Epithelial Ovarian Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Malignant Epithelial Pleaural Mesothelioma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CART-meso</intervention_name>
    <description>CART-meso are autologous T cells lentivirally transduced with chimeric anti-mesothelin immunoreceptor SS1 fused to the 4-1BB and CD3ζ signaling domains.</description>
    <arm_group_label>Malignant Epithelial Pleaural Mesothelioma</arm_group_label>
    <arm_group_label>Metastatic Pancreatic (ductal) adenocarcinoma (PDA)</arm_group_label>
    <arm_group_label>Serious Epithelial Ovarian Cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed cancer (one of the following):&#xD;
&#xD;
               -  Metastatic pancreatic adenocarcinoma.&#xD;
&#xD;
               -  Persistent or recurrent serous epithelial ovarian cancer or primary peritoneal&#xD;
                  carcinoma&#xD;
&#xD;
               -  Malignant pleural mesothelioma (histologically confirmed epithelial)&#xD;
&#xD;
          -  Failure of at least one prior standard of care chemotherapy for advanced stage&#xD;
             disease.&#xD;
&#xD;
          -  Subjects must have measureable disease as defined by RECIST 1.1 criteria or modified&#xD;
             RECIST criteria.&#xD;
&#xD;
          -  Patients &gt; 18 years of age.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          -  Life expectancy &gt; 3 months.&#xD;
&#xD;
          -  Satisfactory organ and bone marrow function as defined by the following (of note, the&#xD;
             minimal blood counts should be in the absence of transfusion or cytokine support):&#xD;
&#xD;
             i. Absolute neutrophil count &gt; 1,000/μl ii. Platelets &gt;75,000/μl iii. Hemoglobin &gt; 9&#xD;
             g/dL iv. Bilirubin &lt; 2.0x the institutional normal upper limit unless secondary to&#xD;
             bile duct obstruction by tumor v. Creatinine &lt; 1.5x the institutional normal upper&#xD;
             limit vi. Albumin ≥2 vii. Serum alanine aminotransferase (ALT) or aspartate&#xD;
             aminotransferase (AST) &lt; 5x the institutional normal upper limit viii. Cardiac&#xD;
             ejection fraction of &gt;55% as measured by resting echocardiogram, with no significant&#xD;
             pericardial effusion.&#xD;
&#xD;
          -  Blood coagulation parameters: PT such that international normalized ratio (INR) is ≤&#xD;
             1.5 and a PTT &lt; 1.2 time the upper limit of normal unless the patient is&#xD;
             therapeutically anti-coagulated for history of cancer-related thrombosis and has&#xD;
             stable coagulation parameters.&#xD;
&#xD;
          -  Ability to understand and the willingness to provide written informed consent.&#xD;
&#xD;
          -  Male and Female subjects of reproductive potential agree to use approved contraceptive&#xD;
             methods (e.g. birth control pills, barrier device, intrauterine device, abstinence)&#xD;
             and abstain from other methods of conception during the study and for 6 months&#xD;
             following the study cell infusion or proof of sterility.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Sarcomatoid MPM histology which is known in the literature to not express mesothelin;&#xD;
             biphasic MPM is also excluded.&#xD;
&#xD;
          -  Participated in any other trial in which receipt of an investigational study drug&#xD;
             occurred within 28 days prior to enrollment and anticipated treatment with another&#xD;
             investigational product while on study. This refers to non-commercially approved&#xD;
             investigational drugs different than those used in this protocol.&#xD;
&#xD;
          -  Anticipated need for systemic chemotherapy within 2 weeks before apheresis and&#xD;
             infusion of CART-meso cells.&#xD;
&#xD;
          -  Active invasive cancer other than the one of the three cancers in this study. Patients&#xD;
             with active non-invasive cancers (such as non-melanoma skin cancer, superficial&#xD;
             cervical and bladder and prostate cancer with PSA level &lt; 1.0) are not&#xD;
             excluded.CART-meso in mesothelin expressing cancers&#xD;
&#xD;
          -  HIV, HCV, or HBV infections&#xD;
&#xD;
          -  Active autoimmune disease (including but not limited to: systemic lupus&#xD;
             erythromatosis, Sjogren's syndrome, rheumatoid arthritis, psoriasis, multiple&#xD;
             sclerosis, inflammatory bowel disease, etc.) requiring immunosuppressive therapy&#xD;
             within the past 4 weeks, with exception of thyroid replacement.&#xD;
&#xD;
          -  Patients with ongoing or active infection.&#xD;
&#xD;
          -  Planned concurrent treatment with systemic high dose corticosteroids. Patients may be&#xD;
             on a stable low dose of steroids (&lt;10mg equivalent of prednisone) for chronic&#xD;
             respiratory conditions.&#xD;
&#xD;
          -  Patients requiring supplemental oxygen therapy.&#xD;
&#xD;
          -  Prior therapy with gene modified cells.&#xD;
&#xD;
          -  Previous experimental therapy with SS1 moiety, murine or chimeric antibodies (human&#xD;
             and humanized antibodies are allowed).&#xD;
&#xD;
          -  History of allergy to murine proteins&#xD;
&#xD;
          -  History of allergy or hypersensitivity to study product excipients (human serum&#xD;
             albumin, DMSO, and Dextran 40)&#xD;
&#xD;
          -  Any clinically significant pericardial effusion; CHF (NY Heart Association Grade&#xD;
             II-IV) or cardiovascular condition that would preclude assessment of mesothelin&#xD;
             induced pericarditis or that may worsen as a result of toxicities expected for this&#xD;
             study. This determination will be made by a cardiologist.&#xD;
&#xD;
          -  Any clinically significant pleural or peritoneal effusion that cannot be drained with&#xD;
             standard approaches. An indwelling drainage device placed prior to enrollment is&#xD;
             acceptable.&#xD;
&#xD;
          -  Pregnant or breastfeeding women. Female study participants of reproductive potential&#xD;
             must have a negative urine pregnancy test of enrollment. A serum pregnancy test will&#xD;
             be performed within 2 weeks before infusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Haas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ambramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Haas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>June 6, 2014</study_first_submitted>
  <study_first_submitted_qc>June 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2014</study_first_posted>
  <last_update_submitted>February 22, 2019</last_update_submitted>
  <last_update_submitted_qc>February 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Subjects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

